Inhibition of an equilibrative nucleoside transporter by cannabidiol: A mechanism of cannabinoid immunosuppression
Top Cited Papers
- 16 May 2006
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 103 (20) , 7895-7900
- https://doi.org/10.1073/pnas.0511232103
Abstract
The plant-derived cannabinoids Δ 9 -tetrahydrocannabinol (THC) and cannabidiol (CBD) both have immunosuppressive effects; although some effects of THC are mediated by the CB 2 receptor, CB 2 binds CBD weakly. In examining the effects of THC and CBD on microglial proliferation, we found that these compounds potently inhibit [ 3 H]thymidine incorporation into a murine microglial cell line with no effect on cell cycle. Treatment with THC and CBD decreased [ 3 H]thymidine uptake into microglia, with IC 50 values that match inhibition of [ 3 H]thymidine incorporation into DNA. CBD and, less potently, THC decreased uptake of [ 3 H]adenosine to a similar extent as [ 3 H]thymidine in both murine microglia and RAW264.7 macrophages. Binding studies confirm that CBD binds to the equilibrative nucleoside transporter 1 with a K i < 250 nM. Because adenosine agonists have antiinflammatory effects, and because uptake of adenosine is a primary mechanism of terminating adenosine signaling, we tested the hypothesis that CBD is immunosuppressive because it enhances endogenous adenosine signaling. In vivo treatment with a low dose of CBD decreases TNFα production in lipopolysaccharide-treated mice; this effect is reversed with an A 2A adenosine receptor antagonist and abolished in A 2A receptor knockout mice. These studies demonstrate that CBD has the ability to enhance adenosine signaling through inhibition of uptake and provide a non-cannabinoid receptor mechanism by which CBD can decrease inflammation.Keywords
This publication has 43 references indexed in Scilit:
- Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivoBlood, 2005
- Low dose oral cannabinoid therapy reduces progression of atherosclerosis in miceNature, 2005
- Adenosine and Epilepsy: From Therapeutic Rationale to New Therapeutic StrategiesThe Neuroscientist, 2005
- Long-Term Administration of Δ9-Tetrahydrocannabinol Desensitizes CB1-, Adenosine A1-, and GABAB-Mediated Inhibition of Adenylyl Cyclase in Mouse CerebellumMolecular Pharmacology, 2004
- Adenosine: an endogenous regulator of innate immunityTrends in Immunology, 2004
- The ENT family of eukaryote nucleoside and nucleobase transporters: recent advances in the investigation of structure/function relationships and the identification of novel isoformsMolecular Membrane Biology, 2001
- Reactive microgliosisProgress in Neurobiology, 1999
- Modulation of Adenosine Effects in Attenuation of Ischemia and Reperfusion Injury in Rat HeartJournal of Molecular and Cellular Cardiology, 1998
- Meetings and Conferences · Tagungen und KongresseOncology Research and Treatment, 1998
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973